Impact of COVID19 on Asthma Patients in Spain

NCT ID: NCT05064501

Last Updated: 2025-11-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Study Classification

OBSERVATIONAL

Study Start Date

2021-02-01

Study Completion Date

2024-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This research project aims to investigate the impact of COVID-19 on asthmatic patients, particularly focusing on whether the viral infection exacerbates asthma or affects control and lung function in the short to medium term. The study plans to collect and compare data from two groups of asthmatic individuals - those who have experienced a SARS-CoV-2 infection requiring emergency consultation or hospitalization and a matched control group without such infection. Both groups will be followed for one year, with lung function tests conducted at six months and monitoring of exacerbations and changes in Asthma Control Test (ACT) throughout the year. The objective is to enhance understanding of how COVID-19 affects asthmatic patients, leading to improved recommendations, preventive measures, and treatment adjustments based on the study's findings.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The COVID19 pandemic is having an immeasurable impact on the economy and on morbidity and mortality. Knowledge and scientific evidence about this disease is advancing rapidly, but it is not yet known whether asthmatic patients suffering from COVID19 have an exacerbation of asthma, or whether this viral infection has an impact on control and lung function in the short to medium term.

The aim of this study is to define the changes that occur in these two parameters in asthmatic patients suffering from COVID19. To this end, asthmatic patients who have suffered a SARS-CoV-2 infection and who have required an emergency consultation or hospitalisation will be collected in a pneumology consultation and matched by age, sex and severity of asthma with a group that has not suffered the same. Both will be followed for one year, and lung function will be tested at six months and exacerbations and changes in ACT during the following year.

These data are intended to improve the available knowledge on the impact of IDVC19 on asthma patients with a view to making appropriate recommendations, prevention and treatment adjustments in line with the results obtained.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Asthma Covid19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Asthma and COVID19 infection

Asthma and COVID19 infection

spirometry

Intervention Type DIAGNOSTIC_TEST

Lung function test: pre and post bronchodilator spirometry

Asthma control test

Intervention Type OTHER

Asthma control test

Asthma without COVID19 infection

Asthma and COVID19 infection

spirometry

Intervention Type DIAGNOSTIC_TEST

Lung function test: pre and post bronchodilator spirometry

Asthma control test

Intervention Type OTHER

Asthma control test

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

spirometry

Lung function test: pre and post bronchodilator spirometry

Intervention Type DIAGNOSTIC_TEST

Asthma control test

Asthma control test

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 12 -80 years
* Asthma diagnosis according to guidelines
* Follow up on asthma clinics in one of the participant hospitals

Exclusion Criteria

* Other severe respiratory condition independent of asthma
Minimum Eligible Age

12 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sociedad Española de Neumología y Cirugía Torácica

OTHER

Sponsor Role collaborator

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

elena Curto, PhD

Role: PRINCIPAL_INVESTIGATOR

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hospital de la Santa Creu i Sant Pau. Carrer Mas Casanovas 90.

Barcelona, , Spain

Site Status

Hospital de la Santa Creu i Sant Pau

Barcelona, , Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Spain

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IIBSP-COV-2020-129

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Bronchial Asthma & Its Exacerbation
NCT06331897 NOT_YET_RECRUITING
COPD in the Time of COVID-19
NCT04407598 UNKNOWN